Sara Orndoff-Snyder, MSN Oncology Account Executive, Pittsburgh, PA CELL: 412.335.0449| EMAIL: sara.orndoff@abbvie.com Come Chat with Sara: Join Zoom Meeting https://abbvie.zoom.us/j/7084120152?pwd=OGZPeFRkQ0QwMkVvMUltcEFhVnk2UT09 Meeting ID: 708 412 0152 Password: 255485 One tap mobile +13017158592,,7084120152# US (Washington D.C) +13126266799,,7084120152# US (Chicago) Dial by your location +1 301 715 8592 US (Washington D.C) +1 312 626 6799 US (Chicago) +1 929 205 6099 US (New York) +1 253 215 8782 US (Tacoma) +1 346 248 7799 US (Houston) +1 669 900 6833 US (San Jose) Meeting ID: 708 412 0152 Find your local number: https://abbvie.zoom.us/u/acxKncLZRR Join from a Video System (Example: Cisco) Password: 255485 Join from a Microsoft Video System (Example: Surface Hub) Password: 255485
CARLI ALLENDORF, MSN, ACNP-BC Thought Leader Liaison, Hematology Franchise CELL 614-352-8603
|
At AbbVie, we strive to discover and develop medicines that deliver transformational improvements in cancer treatment by uniquely combining our deep knowledge in core areas of biology with cutting-edge technologies, and by working together with our partners – scientists, clinical experts, industry peers, advocates, and patients. We remain focused on delivering these transformative advances in treatment across some of the most debilitating and widespread cancers. We are also committed to exploring solutions to help patients obtain access to our cancer medicines. AbbVie's oncology portfolio now consists of marketed medicines and a pipeline containing multiple new molecules being evaluated worldwide in more than 300 clinical trials and more than 20 different tumor types. For more information, please visit http://www.abbvie.com/oncology.
venclexta-patient-initiation-checklist.pdf VENCLEXTA-Treatment-Guide_CLL.pdf VENCLEXTA-Treatment-Guide_CLL.pdf
| Back to the Virtual Exhibit Hall
|